Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Revolution Medicines, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering precision oncology therapies that target RAS-driven cancers, a historically difficult class of oncogenic drivers. The company operates within the biopharmaceutical and oncology drug development industry, with a strategic emphasis on small-molecule inhibitors designed to selectively target mutant and wild-type RAS signaling pathways. Its core objective is to address cancers with high unmet medical need, particularly those driven by KRAS mutations.
Founded in 2014, Revolution Medicines was established to translate advances in RAS biology into therapeutically viable drugs. The company has evolved from a discovery-focused organization into a late-stage clinical developer with multiple assets in human trials. Its differentiation lies in its proprietary tri-complex inhibitor platform, which enables selective inhibition of RAS signaling, positioning the company as a leader in next-generation RAS-targeted oncology therapeutics.
Business Operations
Revolution Medicines’ operations are centered on drug discovery, preclinical research, and clinical development, with revenue generation not yet commercialized and funding primarily derived from equity offerings and strategic collaborations. Its primary operating segments consist of research and development and general and administrative operations, consistent with its clinical-stage profile. The company does not currently report product revenue and has not yet brought a therapy to market.
The company’s pipeline includes multiple clinical and preclinical candidates targeting KRAS mutations, notably RMC-6236, RMC-6291, and RMC-9805, which are being evaluated across various solid tumor indications. Revolution Medicines conducts clinical trials globally through contracted research organizations and maintains internal capabilities in medicinal chemistry, translational biology, and clinical strategy. It does not rely on manufacturing assets, instead utilizing third-party manufacturers for clinical trial materials.
Strategic Position & Investments
Strategically, Revolution Medicines is focused on establishing itself as a category leader in RAS inhibition, advancing both monotherapy and combination therapy approaches. Its growth strategy prioritizes accelerating late-stage clinical development, expanding its pipeline into additional RAS-driven indications, and leveraging combination regimens with other targeted or immuno-oncology agents. The company has articulated a long-term vision of building a sustainable oncology franchise anchored in RAS biology.
Revolution Medicines has made targeted investments in platform development rather than large-scale acquisitions. A notable strategic partnership includes collaboration with Sanofi for the development of certain RAS-targeted therapies, providing external validation and financial support. As of available public disclosures, the company does not operate through a complex subsidiary structure, and its value is concentrated in its wholly owned pipeline assets and intellectual property portfolio.
Geographic Footprint
Revolution Medicines is headquartered in Redwood City, California, within the United States, and its core operations are primarily U.S.-based. Research, development, and corporate functions are centralized at its California facilities, reflecting its focus on innovation and proximity to the biotechnology ecosystem.
Internationally, the company’s presence is primarily operational rather than physical, with clinical trial activities conducted across North America, Europe, and parts of Asia-Pacific through global clinical research networks. While it does not maintain significant overseas offices, its clinical development strategy gives it a growing global footprint and exposure to international regulatory environments and patient populations.
Leadership & Governance
Revolution Medicines was co-founded by Mark A. Goldsmith, who has played a central role in shaping the company’s scientific vision and long-term strategy. The leadership team combines deep expertise in oncology drug development, translational science, and biopharmaceutical operations. Governance is overseen by an independent board with experience across biotechnology, large pharmaceutical companies, and capital markets.
Key executives are aligned around a strategy focused on scientific rigor, disciplined capital allocation, and advancing transformative therapies for patients with limited treatment options. Management has consistently emphasized long-term value creation through differentiated science rather than near-term commercialization.
- Mark A. Goldsmith – Chief Executive Officer
- David P. Southwell – Chief Financial Officer
- Michael R. Dwyer – Chief Development Officer
- Stewart J. Lyman – Chief Legal Officer and Secretary
- K. Peter Schlessinger – President of Research and Development